Source: Annual Congress 2002 - Thoracic oncology: clinical management
Disease area: Thoracic oncology

Abstract

We investigated the efficacy of D in combination with C in the treatment of NSCLC pts. Since 1996, 184 pts with inoperable NSCLC has been enrolled in the study; 180 (154 M, 26 F median age 50,5 years) were evaluated. Of those, 60 pts had squamous carcinoma, 79 adenocarcinoma and 26 undifferentiated tumors. Eligibility criteria induced, documented inoperable NSCLC, WHO PS 0-1, age up to 73 years and normal renal and hepatic function. A total of 1156 cycles of chemotherapy (median 6 courses per patient) were administered. Each cycle consisted of 100 mg/m² of D in a 2-h infusion with C at a dose of AUC 6 on D1. These regimens were repeated every 28 days up to eight cycles. Sixteen patients (8,8%) achieved complete response, 60 (33,3%) partial response, 82 (45,5%) had stable disease and 22 (12%) had progressive disease. The median survival was 514 days (95% CI 426,5 - 601,4) for all pts, 961,33 for six pts with stage IIb disease, 797 for the 23 (12,7%) pts with IIIa stage disease, 698 days for the 51 (28,3%) pts with IIIb stage disease and 411 days for the 100 (55,5%) pts with stage IV. The median time to progression was 244 days (130 patients). Toxicity was, grade 3/4 neutropenia 15.6%, grade 3 /4 anemia, 4%; and torelable peripheral neuropathy 8,7%. Responders received radiotherapy (total dose 50 Gy in four weeks) between the 6^th and 8^th cycle. Among responders with initial stage IIIb disease 7 (3,8%) underwent surgical resection. Patients with early progression of the disease received the same dose of radiotherapy between 2^nd and 3^rd cycle. Preliminary results indicate that the D/C combination is very active in the treatment of NSCLC and with tolerable toxicity.

Rating:

Share or cite this content

Citations should be made in the following way:
K. Zarogoulidis, A. Xafenias, P. Panousis, T. Kontakiotis, D. Iakovidis, D. Patakas (Thessaloniki, Greece). A phase II study of docetaxel in combination with carboplatin in the treatment of non-small cell lung cancer patients. Eur Respir J 2002; 20: Suppl. 38, 1189

Member's Comments

No comment yet.

Related content which might interest you: Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 Gemcitabine, ifosfamide and paclitaxel in patients with untreated advanced/metastatic nonsmall cell lung cancer (NSCLC) A phase II study Source: Eur Respir J 2003; 22: Suppl. 45, 28s Year: 2003 Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 Phase II trial of docetaxel and carboplatin in previously untreated patients with non-small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001 Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer (NSCLC), a phase II multi-institutional trial Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002 A phase II trial in patients with extensive disease small-cell lung cancer with irinotecan, carboplatin and etoposide regimen as a first line treatment Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006 Weekly chemotherapy with cisplatin and paclitaxel in inoperable advanced non-small cell lung cancer: an extended phase II study Source: Eur Respir J 2005; 26: Suppl. 49, 12s Year: 2005 First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial Source: Eur Respir J, 56 (2) 1902066; 10.1183/13993003.02066-2019 Year: 2020 Biweekly carboplatin-gemcitabine administration in elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007 A phase I trial of combined carboplatin and topotecan as 2nd line treatment in patients (pts) with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003 Docetaxel in combination with carboplatin in the treatment of Stage IIIb and IV non-small cell lung cancer patients. A Phase II study Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005 A three-arms phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 318s Year: 2001 Docetaxel in combination with cisplatin in patients with advanced non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 Phase I/II study of biweekly docetaxel/cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 A randomised prospective trial of concurrent chemoradiotherapy (CCRT) with cisplatin and paclitaxel or docetaxel or gemcitabine in stage IIIB nonsmall cell lung cancer Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer Year: 2009 Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 241s Year: 2007 A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003 Implementation study: role of docetaxel after a first line cisplatinum based chemotherapy for non-small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004 A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016